Compare Dolby Laboratories, Inc. (DLB) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Immunovant Inc. Common Stock — how do they compare? Dolby Laboratories, Inc. trades at $58.47 (market cap $5.47B), while Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B). The key difference: Immunovant Inc. Common Stock is the larger of the two by market cap, and Dolby Laboratories, Inc. pays a 2.47% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Immunovant Inc. Common Stock for 0 Days on average.
| DLB | IMVT | |
|---|---|---|
Market Cap | $5.47B | $6.62B |
Volume | 691,016 | 1,131,364 |
Sector | Technology | Health |
52-Week High | $70.09 | $44.96 |
52-Week Low | $48.51 | $17.03 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $4.84B | $5.72B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.35, down 0.19% with bearish technical signals despite strong profitability margins. The company maintains robust fundamentals with 87.61% gross margins and consistent earnings beats, though revenue has plateaued around $1.3B. Recent leadership transition to Marc Whitten and expanded Meta partnership for Dolby Atmos/Vision represent key developments. Technical indicators show resistance at $59 with support at $58.
DLB offers stable cash flow generation and dividend income but faces growth challenges with flat revenue. Analyst consensus targets $90.33 (55% upside) with 47% buy ratings, though near-term execution risks and licensing volatility warrant caution. The stock presents value for income investors but requires revenue acceleration for significant appreciation.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
